← Back to Directory

Arrowhead Pharmaceuticals, Inc. (ARWR) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Arrowhead Pharmaceuticals, Inc. (ARWR).

Download S&P Stocks on Google Play Download S&P Stocks on the App Store

Equity Details

Price & Market Data

Price: $79.04

Daily Change: +$1.30 / 1.64%

Daily Range: $76.59 - $79.59

Market Cap: $11,133,339,648

Daily Volume: 1,533,352

Performance Metrics

1 Week: 5.49%

1 Month: 23.91%

3 Months: 25.62%

6 Months: 101.5%

1 Year: 465.8%

YTD: 19.05%

About Arrowhead Pharmaceuticals, Inc. (ARWR)

Analyze the market position of Arrowhead Pharmaceuticals, Inc. (ARWR). With a current price of 79.04, the stock exhibits a +$1.30 / 1.64% daily trend. A market capitalization of 11,133,339,648 indicates its scale. Discover its performance over 1-month (23.91%) and 3-month (25.62%) periods.

Company Details

Employees: 711

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Selected stocks

Dycom Industries, Inc. (DY)

CenterPoint Energy, Inc (Holding Co) (CNP)

WSFS Financial Corporation (WSFS)

Stifel Financial Corporation (SF)

Parker-Hannifin Corporation (PH)